



Alzheimer Disease: Controversies in Basic Science Research, Different Theories, and Reasons for Failed Trials

Guest Editor:

Dr. Farid Rahimi

Division of Biomedical Science
and Biochemistry, Research
School of Biology, ANU College of
Science, The Australian National
University, Canberra, ACT 2600,
Australia

Deadline for manuscript
submissions:

closed (30 November 2020)

Message from the Guest Editor

Dear Colleagues,

AD is a predominant, devastating, progressive chronic disease that begins as episodic memory lapses and progresses to changes in mood and personality and a decline of mental capacities. AD typically afflicts patients in their eighth or ninth decade of life, and its incidence rises steeply after 65 years of age. The global statistics on AD prevalence are ominous, and the 2018 cost of care is projected to be billions in the US alone. The emotional and spiritual costs to any family of a patient with dementia are immeasurable and irreplaceable. Such forbidding statistics has established AD as a profoundly disconcerting and very costly global health crisis.

The aims of this Special Issue are to 1) highlight controversies or shortcomings of basic scientific research into AD so to help refocus research endeavours tackling AD; 2) collect reviews or original research articles that would potentially link the various theories on the aetiology and pathogenesis of AD and provide potentially unifying theories; and 3) collect analyses or discussions of the various reasons why so many clinical trials based on predominant theories of AD have failed so far.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)